https://doi.org/10.4081/monaldi.2025.3129
Inhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 22 January 2025
The term “asthma-chronic obstructive pulmonary disease (COPD) combined phenotype” describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD. This study is a prospective interventional study that included 43 patients diagnosed with the asthma-COPD overlap phenotype, as per Sin et al. criteria, who were treated as COPD previously and followed over 1 year. These patients received additional treatment with a moderate-dose ICS metered-dose inhaler, beclamethasone 800 mcg daily, in addition to their optimal inhaled bronchodilator therapy. Follow-up spirometry, along with reversibility, fractional exhaled nitric oxide (FeNO), and blood investigations like total eosinophil count (TEC) and immunoglobulin E (IgE) were done; sputum eosinophils were measured, and a history of exacerbations was noted. These parameters were compared with baseline values obtained prior to the initiation of ICS to evaluate the impact of the intervention. Among the 43 individuals in the study population, the majority fell within the age group of 60-69 years. The addition of ICS to bronchodilators over a 1-year period resulted in significant improvements in their forced expiratory volume in one second. Additionally, there was a notable reduction in the FeNO level, along with decreases in the TEC, serum IgE levels, and sputum eosinophils. Although the number of exacerbations decreased during the study period in this subgroup, this reduction did not reach statistical significance. Based on these findings, the study suggests that ICS should be considered as an adjunct to inhaled bronchodilators for the management of stable COPD patients exhibiting features of the asthma-COPD combined phenotype.
Downloads
Venkata AN. Asthma-COPD overlap: review of diagnosis and management. Curr Opin Pulm Med 2020;26:155-61. DOI: https://doi.org/10.1097/MCP.0000000000000649
Global Initiative for Asthma, Global Initiative for Chronic Obstructive Lung Disease. Diagnosis of diseases of chronic airfow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS). 2015. Available from: https://goldcopd.org/wp-content/uploads/2016/04/GOLD_ACOS_2015.pdf. DOI: https://doi.org/10.1016/j.ypdi.2016.03.003
Global Initiative for Asthma. Global strategy for asthma management and prevention, global initiative for asthma (GINA). 2019. Available from: http://www.ginasthma.org/.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2020. Available from: https://goldcopd.org/gold-reports/.
Barrecheguren M, Roman-Rodriguez M, Miravitlles M. Is a previous diagnosis of asthma a reliable criterion for asthma-COPD overlap syndrome in a patient with COPD? Int J Chron Obstruct Pulmon Dis 2015;10:1745-52. DOI: https://doi.org/10.2147/COPD.S87025
Wurst KE, Rheault TR, Edwards L, et al. A comparison of COPD patients with and without ACOS in the ECLIPSE study. Eur Respir J 2016;47:1559-62. DOI: https://doi.org/10.1183/13993003.02045-2015
Chen FJ, Huang XY, Liu YL, et al. Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPD. Int J Chron Obstruct Pulmon Dis 2016;11:2385-90. DOI: https://doi.org/10.2147/COPD.S115378
Takayama Y, Ohnishi H, Ogasawara F, et al. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis 2018;13:2525-32. DOI: https://doi.org/10.2147/COPD.S167600
Lange P, Colak Y, Ingebrigtsen TS, et al. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. Lancet Respir Med 2016;4:454-62. DOI: https://doi.org/10.1016/S2213-2600(16)00098-9
Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016;48:664-73. DOI: https://doi.org/10.1183/13993003.00436-2016
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200:e70-88. DOI: https://doi.org/10.1164/rccm.201908-1590ST
Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD Overlap Syndrome (ACOS): a systematic review and meta analysis. PLoS One 2015;10:e0136065. DOI: https://doi.org/10.1371/journal.pone.0136065
Renthlei L, Wangkheimayum A, Kshetrimayum S, et al. Prevalence and characteristics of asthma‑chronic obstructive pulmonary disease overlap among asthma and chronic obstructive pulmonary disease patients in a tertiary care center in Northeast India. J Med Soc 2019;33:122-7. DOI: https://doi.org/10.4103/jms.jms_9_19
Hashimoto S, Sorimachi R, Jinnai T, Ichinose M. Asthma and chronic obstructive pulmonary disease overlap according to the Japanese respiratory society diagnostic criteria: the prospective, observational ACO Japan cohort study. Adv Ther 2021;38:1168-84. DOI: https://doi.org/10.1007/s12325-020-01573-x
Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest 2016;149:45-52. DOI: https://doi.org/10.1378/chest.15-1055
Feng JX, Lin Y, Lin J, et al. relationship between fractional exhaled nitric oxide level and efficacy of inhaled corticosteroid in asthma-COPD overlap syndrome patients with different disease severity. J Korean Med Sci 2017;32:439-47. DOI: https://doi.org/10.3346/jkms.2017.32.3.439
Lee SY, Park HY, Kim EK, et al. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 2016;11:2797-803. DOI: https://doi.org/10.2147/COPD.S114964
Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016;47:1374-82. DOI: https://doi.org/10.1183/13993003.01370-2015
Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med 2015;21:74-9. DOI: https://doi.org/10.1097/MCP.0000000000000118
Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012;7:283-9. DOI: https://doi.org/10.2147/COPD.S30651
Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42. DOI: https://doi.org/10.1016/S2213-2600(15)00106-X
Kobayashi S, Hanagama M, Yamanda S, et al. Inflammatory biomarkers in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 2016;11:2117-23. DOI: https://doi.org/10.2147/COPD.S113647
Yamaji Y, Oishi K, Hamada K, et al. Detection of type2 biomarkers for response in COPD. J Breath Res 2020;14:026007. DOI: https://doi.org/10.1088/1752-7163/ab71a4
Izquierdo-Alonso JL, Rodriguez-Gonzalezmoro JM, de Lucas-Ramos P, et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013;107:724-31. DOI: https://doi.org/10.1016/j.rmed.2013.01.001
Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523-5. DOI: https://doi.org/10.1164/rccm.201502-0235LE
Ethics Approval
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.